Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.

View Full Paper
Ask AI
Bookmark
Share

Authors

SGStéphanie GuidezMRMarie‐Thérèse RubioMCMorgane Cheminant

Discussion

Loading...

Member takes

Overview

Analysis reveals CAR-T therapy improves survival in patients with CNS-involved mantle cell lymphoma, highlighting risks of neurotoxicity and cytokine release syndrome.

Key Points

  • This research aims to evaluate the effectiveness of CAR-T therapy for mantle cell lymphoma with CNS involvement.
  • Analyzed data from French DESCAR-T registry for MCLSNC cases treated with CAR T-cells between 2020 and 2024
  • Identified 20 cases with documented CNS involvement
  • Assessed clinical outcomes after CAR-T therapy administration
  • 50% of patients achieved a complete response at one month post-infusion
  • Median progression-free survival was 10.2 months
  • Neurotoxicity occurred in 85% of patients, with varying grades of severity

Cite This Study

Guidez et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da1dhttps://doi.org/10.1182/blood-2025-3598
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Association of CAR T cell kinetics with outcomes after standard of care brexucabtagene autoleucel for relapsed/refractory Mantle Cell Lymphoma2025
  2. 2P14.07.B CAR T-CELL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS: A MULTICENTER RETROSPECTIVE STUDY FROM THE LOC NETWORK2025
  3. 3Tandem combination of <scp>ASCT</scp> and <scp>CAR</scp> T‐cell therapy in highly refractory <scp>CNS</scp> lymphomas2025
  4. 4Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  5. 5Outcomes of CD-19–directed CAR-T therapy in patients with primary and secondary central nervous system lymphoma: A multi-center observational study.2026